ASND | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.96%

1 Month

6.84%

3 Months

14.60%

6 Months

15.66%

1 Year

56.66%

2 Year

62.55%

Key data

Stock price

$237.35

P/E Ratio

0.00

DAY RANGE

$234.88 - $240.77

EPS

-$5.07

52 WEEK RANGE

$124.06 - $248.60

52 WEEK CHANGE

$62.86

MARKET CAP

7.945 B

YIELD

N/A

SHARES OUTSTANDING

58.231 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

09-02-2025

BETA

0.88

PUBLIC FLOAT

AVERAGE 10 VOLUME

$840,910

AVERAGE 30 VOLUME

$855,878

Company detail

CEO: Jan M. Mikkelsen
Region: US
Website: ascendispharma.com
Employees: 640
IPO year: 2008

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

ASND - Ascendis Pharma A/S